Hepatic steatosis, carotid plaques and achieving MDA in Psoriatic arthritis patients starting TNF-α blockers treatment: A prospective study

Matteo Nicola Dario Di Minno, Rosario Peluso, Salvatore Iervolino, Roberta Lupoli, Anna Russolillo, Giovanni Tarantino, Raffaele Scarpa

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Introduction: We prospectively evaluated whether hepatic steatosis (HS) and the presence of carotid plaques (CPs) impacts on achieving minimal disease activity (MDA) in psoriatic arthritis (PsA) patients starting tumor necrosis factor (TNF)-α blockers treatment.Methods: Before starting treatment with TNF-α blockers, consecutive PsA subjects with an active disease were evaluated for the presence of the metabolic syndrome (MetS), HS and CPs. The incidence of MDA was evaluated 12 and 24 months later.Results: Among 270 PsA subjects, 91 (33.7%) exhibited the MetS, 58 (21.5%) CPs and 76 (28.1%) HS. At the 12-month follow-up, 98 (36.3%) individuals achieved MDA. Compared with those who did, a higher prevalence of the MetS, HS and CPs was found in subjects who did not achieve the MDA (P always <0.001). After adjusting for the MetS and for all the other demographic/clinical characteristics analyzed, the presence of HS and CPs at baseline independently predicted the risk of not achieving MDA (Hazard Ratio: 1.91, 95% confidence interval (CI): 1.04 to 3.38, P = 0.035 and Hazard Ratio: 3.21, 95%CI: 1.64 to 6.29, P = 0.001, respectively). Separate Kaplan-Meier survival models confirmed this (Log-Rank: 12.894, P <0.001 and Log-Rank: 12.849, P <0.001, respectively). Compared with those without, progressively increasing Hazard Ratios of not achieving MDA were found in those with HS, CPs or HS + CPs at baseline. Moreover, the presence of HS and/or CPs predicted the risk of relapse during the additional 12-month follow-up (Hazard Ratio: 2.85, 95%CI: 1.27 to 6.37, P = 0.011 and Hazard Ratio: 3.17, 95%CI: 1.57 to 6.41, P = 0.001 respectively).Conclusions: HS and/or CPs at baseline are negative predictors of achieving and maintaining MDA.

Original languageEnglish
Article numberR211
JournalArthritis Research and Therapy
Volume14
Issue number5
DOIs
Publication statusPublished - Oct 4 2012

Fingerprint

Psoriatic Arthritis
Tumor Necrosis Factor-alpha
Prospective Studies
Liver
Confidence Intervals
Therapeutics
Demography
Recurrence
Survival
Incidence

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Hepatic steatosis, carotid plaques and achieving MDA in Psoriatic arthritis patients starting TNF-α blockers treatment : A prospective study. / Di Minno, Matteo Nicola Dario; Peluso, Rosario; Iervolino, Salvatore; Lupoli, Roberta; Russolillo, Anna; Tarantino, Giovanni; Scarpa, Raffaele.

In: Arthritis Research and Therapy, Vol. 14, No. 5, R211, 04.10.2012.

Research output: Contribution to journalArticle

Di Minno, Matteo Nicola Dario ; Peluso, Rosario ; Iervolino, Salvatore ; Lupoli, Roberta ; Russolillo, Anna ; Tarantino, Giovanni ; Scarpa, Raffaele. / Hepatic steatosis, carotid plaques and achieving MDA in Psoriatic arthritis patients starting TNF-α blockers treatment : A prospective study. In: Arthritis Research and Therapy. 2012 ; Vol. 14, No. 5.
@article{ea24e6e110514418ab1c7c5e07bb7dfe,
title = "Hepatic steatosis, carotid plaques and achieving MDA in Psoriatic arthritis patients starting TNF-α blockers treatment: A prospective study",
abstract = "Introduction: We prospectively evaluated whether hepatic steatosis (HS) and the presence of carotid plaques (CPs) impacts on achieving minimal disease activity (MDA) in psoriatic arthritis (PsA) patients starting tumor necrosis factor (TNF)-α blockers treatment.Methods: Before starting treatment with TNF-α blockers, consecutive PsA subjects with an active disease were evaluated for the presence of the metabolic syndrome (MetS), HS and CPs. The incidence of MDA was evaluated 12 and 24 months later.Results: Among 270 PsA subjects, 91 (33.7{\%}) exhibited the MetS, 58 (21.5{\%}) CPs and 76 (28.1{\%}) HS. At the 12-month follow-up, 98 (36.3{\%}) individuals achieved MDA. Compared with those who did, a higher prevalence of the MetS, HS and CPs was found in subjects who did not achieve the MDA (P always <0.001). After adjusting for the MetS and for all the other demographic/clinical characteristics analyzed, the presence of HS and CPs at baseline independently predicted the risk of not achieving MDA (Hazard Ratio: 1.91, 95{\%} confidence interval (CI): 1.04 to 3.38, P = 0.035 and Hazard Ratio: 3.21, 95{\%}CI: 1.64 to 6.29, P = 0.001, respectively). Separate Kaplan-Meier survival models confirmed this (Log-Rank: 12.894, P <0.001 and Log-Rank: 12.849, P <0.001, respectively). Compared with those without, progressively increasing Hazard Ratios of not achieving MDA were found in those with HS, CPs or HS + CPs at baseline. Moreover, the presence of HS and/or CPs predicted the risk of relapse during the additional 12-month follow-up (Hazard Ratio: 2.85, 95{\%}CI: 1.27 to 6.37, P = 0.011 and Hazard Ratio: 3.17, 95{\%}CI: 1.57 to 6.41, P = 0.001 respectively).Conclusions: HS and/or CPs at baseline are negative predictors of achieving and maintaining MDA.",
author = "{Di Minno}, {Matteo Nicola Dario} and Rosario Peluso and Salvatore Iervolino and Roberta Lupoli and Anna Russolillo and Giovanni Tarantino and Raffaele Scarpa",
year = "2012",
month = "10",
day = "4",
doi = "10.1186/ar4049",
language = "English",
volume = "14",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "5",

}

TY - JOUR

T1 - Hepatic steatosis, carotid plaques and achieving MDA in Psoriatic arthritis patients starting TNF-α blockers treatment

T2 - A prospective study

AU - Di Minno, Matteo Nicola Dario

AU - Peluso, Rosario

AU - Iervolino, Salvatore

AU - Lupoli, Roberta

AU - Russolillo, Anna

AU - Tarantino, Giovanni

AU - Scarpa, Raffaele

PY - 2012/10/4

Y1 - 2012/10/4

N2 - Introduction: We prospectively evaluated whether hepatic steatosis (HS) and the presence of carotid plaques (CPs) impacts on achieving minimal disease activity (MDA) in psoriatic arthritis (PsA) patients starting tumor necrosis factor (TNF)-α blockers treatment.Methods: Before starting treatment with TNF-α blockers, consecutive PsA subjects with an active disease were evaluated for the presence of the metabolic syndrome (MetS), HS and CPs. The incidence of MDA was evaluated 12 and 24 months later.Results: Among 270 PsA subjects, 91 (33.7%) exhibited the MetS, 58 (21.5%) CPs and 76 (28.1%) HS. At the 12-month follow-up, 98 (36.3%) individuals achieved MDA. Compared with those who did, a higher prevalence of the MetS, HS and CPs was found in subjects who did not achieve the MDA (P always <0.001). After adjusting for the MetS and for all the other demographic/clinical characteristics analyzed, the presence of HS and CPs at baseline independently predicted the risk of not achieving MDA (Hazard Ratio: 1.91, 95% confidence interval (CI): 1.04 to 3.38, P = 0.035 and Hazard Ratio: 3.21, 95%CI: 1.64 to 6.29, P = 0.001, respectively). Separate Kaplan-Meier survival models confirmed this (Log-Rank: 12.894, P <0.001 and Log-Rank: 12.849, P <0.001, respectively). Compared with those without, progressively increasing Hazard Ratios of not achieving MDA were found in those with HS, CPs or HS + CPs at baseline. Moreover, the presence of HS and/or CPs predicted the risk of relapse during the additional 12-month follow-up (Hazard Ratio: 2.85, 95%CI: 1.27 to 6.37, P = 0.011 and Hazard Ratio: 3.17, 95%CI: 1.57 to 6.41, P = 0.001 respectively).Conclusions: HS and/or CPs at baseline are negative predictors of achieving and maintaining MDA.

AB - Introduction: We prospectively evaluated whether hepatic steatosis (HS) and the presence of carotid plaques (CPs) impacts on achieving minimal disease activity (MDA) in psoriatic arthritis (PsA) patients starting tumor necrosis factor (TNF)-α blockers treatment.Methods: Before starting treatment with TNF-α blockers, consecutive PsA subjects with an active disease were evaluated for the presence of the metabolic syndrome (MetS), HS and CPs. The incidence of MDA was evaluated 12 and 24 months later.Results: Among 270 PsA subjects, 91 (33.7%) exhibited the MetS, 58 (21.5%) CPs and 76 (28.1%) HS. At the 12-month follow-up, 98 (36.3%) individuals achieved MDA. Compared with those who did, a higher prevalence of the MetS, HS and CPs was found in subjects who did not achieve the MDA (P always <0.001). After adjusting for the MetS and for all the other demographic/clinical characteristics analyzed, the presence of HS and CPs at baseline independently predicted the risk of not achieving MDA (Hazard Ratio: 1.91, 95% confidence interval (CI): 1.04 to 3.38, P = 0.035 and Hazard Ratio: 3.21, 95%CI: 1.64 to 6.29, P = 0.001, respectively). Separate Kaplan-Meier survival models confirmed this (Log-Rank: 12.894, P <0.001 and Log-Rank: 12.849, P <0.001, respectively). Compared with those without, progressively increasing Hazard Ratios of not achieving MDA were found in those with HS, CPs or HS + CPs at baseline. Moreover, the presence of HS and/or CPs predicted the risk of relapse during the additional 12-month follow-up (Hazard Ratio: 2.85, 95%CI: 1.27 to 6.37, P = 0.011 and Hazard Ratio: 3.17, 95%CI: 1.57 to 6.41, P = 0.001 respectively).Conclusions: HS and/or CPs at baseline are negative predictors of achieving and maintaining MDA.

UR - http://www.scopus.com/inward/record.url?scp=84866931057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866931057&partnerID=8YFLogxK

U2 - 10.1186/ar4049

DO - 10.1186/ar4049

M3 - Article

C2 - 23036698

AN - SCOPUS:84866931057

VL - 14

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 5

M1 - R211

ER -